Shares of Novo Nordisk fell sharply after the company announced that its late-stage trial for the heart drug ziltivekimab did not significantly reduce major cardiovascular events like heart attack, stroke, or cardiovascular death compared to a placebo. Although the drug showed some biological activity, it failed to achieve the hoped-for clinical benefits. Novo Nordisk's chief scientific officer emphasized that the company remains committed to cardiovascular disease research despite this setback. The stock dropped about 8.6% in Copenhagen and nearly 10% in U.S. premarket trading.
Deutsche Bank downgraded Novo Nordisk shares from 'hold' to 'sell', cutting the target price by 9% due to concerns over midterm growth and pipeline setbacks. The downgrade follows a mixed Q2 update and highlights worries about limited Medicare prescr...
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
Novo Nordisk's stock appears to have formed a long-term bottom as its turnaround gains momentum, with losses in market share to Eli Lilly stabilizing. Trading at just over 15 times forward earnings, the stock is valued at about half of Eli Lilly's mu...
